These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

783 related items for PubMed ID: 15629415

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH, Gould E.
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.
    Matsumoto AK, Babul N, Ahdieh H.
    Pain Med; 2005 Feb; 6(5):357-66. PubMed ID: 16266356
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
    Aqua K, Gimbel JS, Singla N, Ma T, Ahdieh H, Kerwin R.
    Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
    Buynak R, Shapiro DY, Okamoto A, Van Hove I, Rauschkolb C, Steup A, Lange B, Lange C, Etropolski M.
    Expert Opin Pharmacother; 2010 Aug; 11(11):1787-804. PubMed ID: 20578811
    [Abstract] [Full Text] [Related]

  • 10. The pain quality response profile of oxymorphone extended release in the treatment of low back pain.
    Gould EM, Jensen MP, Victor TW, Gammaitoni AR, White RE, Galer BS.
    Clin J Pain; 2009 Feb; 25(2):116-22. PubMed ID: 19333156
    [Abstract] [Full Text] [Related]

  • 11. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study.
    Gabrail NY, Dvergsten C, Ahdieh H.
    Curr Med Res Opin; 2004 Jun; 20(6):911-8. PubMed ID: 15200750
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.
    Yu S, Shen W, Yu L, Hou Y, Han J, Richards HM.
    J Pain; 2014 Aug; 15(8):835-44. PubMed ID: 24846822
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
    Hartrick C, Van Hove I, Stegmann JU, Oh C, Upmalis D.
    Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
    [Abstract] [Full Text] [Related]

  • 14. Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.
    Kopecky EA, Vaughn B, Lagasse S, O'Connor M.
    Drugs Aging; 2017 Aug; 34(8):603-613. PubMed ID: 28600725
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.
    Biondi D, Xiang J, Benson C, Etropolski M, Moskovitz B, Rauschkolb C.
    Pain Physician; 2013 Aug; 16(3):E237-46. PubMed ID: 23703422
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Analgesic efficacy and tolerability of intravenous morphine versus combined intravenous morphine and oxycodone in a 2-center, randomized, double-blind, pilot trial of patients with moderate to severe pain after total hip replacement.
    Joppich R, Richards P, Kelen R, Stern W, Zarghooni K, Otto C, Böhmer A, Petzke F, Treptau T, Lefering R, Bäthis H, Neugebauer E.
    Clin Ther; 2012 Aug; 34(8):1751-60. PubMed ID: 22795613
    [Abstract] [Full Text] [Related]

  • 20. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex.
    Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Friedmann N.
    J Pain; 2005 Jun; 6(6):392-9. PubMed ID: 15943961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.